Saltar al contenido
Merck
Todas las fotos(5)

Key Documents

SAB3501110

Sigma-Aldrich

Anti-SARS-CoV-2 (COVID-19) Spike antibody produced in rabbit

affinity isolated antibody

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

liquid

species reactivity

SARS coronavirus

concentration

1 mg/mL

technique(s)

ELISA: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable

isotype

IgG

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

SARS coronavirus ... S(43740568)

General description

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak. The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection. The spike protein is the major target for neutralizing antibodies and vaccine development. The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19. The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein.

Immunogen

Anti-SARS-CoV-2 (COVID-19) Spike antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein.

Application

Antibody validated: Immunofluorescence and Western blot in human samples. Immunohistochemistry and immunofluorescence in COVID-19 patient samples. It will detect 4 ng of free peptide at 1 μg/mL. The immunogen for this is within the last 50 aa of the spike protein - a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein. The Extracellular domain (ECD) is from aa 1 to 1208 (full length 1273aa). Therefore, this antibody detects the transmembrane and cytoplasm domains at the C terminus, but does not detect the ECD (which is the region expressed in many commercially available spike proteins). 3525 can be used for the detection of full length spike protein and spike protein in COVID-19 patient samples. All other applications and species not yet tested.

Physical form

Supplied in PBS containing 0.02% sodium azide.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Storage Class

12 - Non Combustible Liquids

wgk_germany

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico